We’re here to help European citizens make sense of stem cells. We provide reliable, independent information and road-tested educational resources on stem cells and their impact on society. We're funded by the European Commission. Learn more.
Prospective PhD student Eilidh Livingston discusses her personal highlight - tissue engineering - from the international Society for Stem Cell Research's annual meeting in Stockholm in June this year. Read on for a nice overview of the topic...
This article is the second in a series of posts about unproven stem cell treatments by guest authors Casimir MacGregor, Alan Petersen and Megan Munsie. Their first post took a closer look at Germany's X-Cell Center and stem cell tourism. Here they consider the regulatory frameworks governing unproven stem cell treatments in Europe, the US and Australia.
The melting pot of expectations, hope, responsibility, idealism and realism in the field of stem cell research were the subject of a panel discussion for media representatives at the recent ISSCR Conference in Stockholm titled “Stem cell research: promise, progress and hype".
All it takes is one molecule to reprogram an antibody-producing B cell into a scavenging macrophage. This transformation is possible, new evidence shows, because the molecule (C/EBPa, a transcription factor) "short-circuits" the cells so that they re-express genes reserved for embryonic development. The findings appear July 30 in Stem Cell Reports, the journal of the International Society for Stem Cell Research.